nach oben

Drugs

Erschienen in:

01.04.2005 | Leading Article

Improving Outcomes in Advanced Malignant Melanoma

Update on Systemic Therapy

verfasst von: Dr Sarah Danson, Paul Lorigan

Erschienen in: Drugs | Ausgabe 6/2005

Einloggen, um Zugang zu erhalten

Abstract

Malignant melanoma continues to increase in incidence throughout the developed world. Surgery remains the cornerstone of curative treatment and the use of adjuvant systemic therapy has provoked much debate. Metastatic disease is incurable in most patients. While combination chemotherapy or biochemotherapy may be considered in certain circumstances, it is now clear that single-agent chemotherapy remains the mainstay of treatment for the majority of patients.

A number of new agents and novel approaches are under evaluation and show promise. The pro-apoptotic agent oblimersen has shown improved progressionfree survival and response rate, although not overall survival, when combined with dacarbazine compared with dacarbazine alone. The BRaf inhibitor sorafenib (BAY 43-9006) has produced encouraging results when administered with chemotherapy and is now being assessed in randomised studies. Thalidomide in combination with chemotherapy is well tolerated and shows a trend towards increased clinical efficacy compared with chemotherapy alone. Other anti-angiogenic drugs, such as bevacizumab, are being investigated in trials. Results with tumour vaccines have been mixed and several large trials are ongoing.

This paper discusses recent pivotal studies and promising new agents in systemic therapy for advanced malignant melanoma.

De Vries E, Bray FI, Coebergh JW, et al. Changing epidemiology of malignant cutaneous melanoma in Europe 1953–1997: rising trends in incidence and mortality but recent stabilisations in Western Europe and decreases in Scandanavia. Int J Cancer 2003; 107(1): 119–26PubMedCrossRef

MacKie RM, Bray CA, Hole DJ, et al. Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lancet 2002; 360: 587–91PubMedCrossRef

Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5–26PubMedCrossRef

Giles D, Dwyer T, Coates M, et al. Trends in skin cancer in Australia: an overview of the available data. Trans Menzies Found 1989; 15: 143–7

Morton DL, Essner R, Calch C. Surgical excision of distant metastases. In: Balch C, Houghton A, Sober A, et al., editors. Cutaneous melanoma. 4th ed. St Louis (MO): Quality Medical Publishing, 2003: 547–72

Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging for cutaneous melanoma. J Clin Oncol 2001; 19: 3635–48PubMed

Middleton MR, Grob JJ, Aaronson N, et al. Randomised phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic melanoma. J Clin Oncol 2000; 18: 158–66PubMed

Millward MJ, Bedikian AY, Conry RM, et al. Randomised multinational phase 3 trial of dacarbazine with or without bcl-2 antisense (oblimersan sodium) in patients with advanced malignant melanoma: analysis of long-term survival [abstract no. 7505]. Proc Am Soc Clin Oncol 2004; 22(145): 22

Lee SM, Betticher DC, Thatcher N. Melanoma: chemotherapy. Br Med Bull 1995; 51: 609–30PubMed

10.

Luikart SD, Kennealey GT, Kirkwood JM. Randomised phase III trial of vinblastine, bleomycin and cis-dichlorodiamineplatinum versus dacarbazine in malignant melanoma. J Clin Oncol 1984; 2: 164–8PubMed

11.

Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicentre randomised trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17: 2745–51PubMed

12.

Middleton M, Lorigan P, Owen J, et al. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer 2000 82: 1158–62PubMedCrossRef

13.

Legha SS. The role of interferon alpha in the treatment of metastatic melanoma. Semin Oncol 1997; 24 (4 Suppl.): S24–31PubMed

14.

Agarwala SS, Glaspy J, O’Day SJ, et al. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 2002; 20: 125–33PubMedCrossRef

15.

Atkins MB, Lotze MT, Dutcher JP, et al. High dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17: 2105–16PubMed

16.

Margolin K, Atkins M, Sparano J, et al. Prospective randomised trial of lisofylline for the prevention of toxicities of high dose interleukin-2 therapy in advanced renal cancer and malignant melanoma. Clin Cancer Res 1997; 3: 365–72

17.

Falkson C, Falkson G, Falkson H. Improved results with the addition of interferon alpha-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 1991; 9: 1403–8PubMed

18.

Huncharek M, Caubet JF, McGarry R. Single-agent dacarbazine versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 2001; 11: 75–81PubMedCrossRef

19.

Keilholz U, Conradt C, Legha SS, et al. Results of interleukin-2 based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 1998; 16(9): 2921–9PubMed

20.

Ernstoff MS. Update: medical therapy for cutaneous melanoma [oral presentation]. American Society of Clinical Oncology (ASCO) 39th Annual Meeting; 2003 May 31–Jun 3; Chicago

21.

Del Vecchio M, Bajetta E, Vitali M, et al. Multicentre phase III randomised trial of cisplatin, vindesine and dacarbazine (CVD) versus CVD plus subcutaneous (sc) interleukin-2 (IL-2) and interferon-alpha-2b (IFN) in metastatic melanoma patients (pts) [abstract no. 2849]. American Society of Clinical Oncology (ASCO) 39th Annual Meeting; 2003 May 31–Jun 3; Chicago

22.

Keilholz U, Punt CJ, Gore M, et al. Dacarbazine, cisplatin and IFN-alpha-2b with or without IL-2 in advanced melanoma: final analysis of EORTC randomised phase III trial 18951 [abstract no. 2848]. American Society of Clinical Oncology (ASCO) 39th Annual Meeting; 2003 May 31–Jun 3; Chicago

23.

Atkins MB, Lee S, Flaherty LE, et al. A prospective randomised phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD) IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-coordinated intergroup trial [abstract no. 2847]. Proc Am Soc Clin Oncol 2003; 22: 708

24.

Newlands ES, Blackledge GR, Slack JA, et al. Phase I trial of temozolomide (CCRG 81045: Mß 39831: NSC 362856). Br J Cancer 1992; 65: 287–91PubMedCrossRef

25.

Bleehan NM, Newlands ES, Lee SM, et al. Cancer Research Campaign phase II trial of temozolomide in malignant melanoma. J Clin Oncol 1995; 13: 910–3

26.

Lee SM, Thatcher N, Crowther D, et al. Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer 1994; 69: 452–6PubMedCrossRef

27.

Su YB, Sohn S, Krown SE, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 2004; 22(3): 610–6PubMedCrossRef

28.

Yung WK, Levin VA, Albright J, et al. A phase II study of temozolomide vs procarbazine in glioblastoma multiforme at first relapse. Br J Cancer 2000; 83: 588–93PubMedCrossRef

29.

Villa S, Verger E, Gil M, et al. Concomitant and adjuvant temozolomide and whole brain irradiation on patients affected with brain metastases: a randomised multicentre phase II trial. Int J Radiat Oncol 2003; 57 (2 Suppl.): S132CrossRef

30.

Stupp R, Mason WP, Van Den Bent MJ, et al. Concomitant and adjuvant temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme: conclusive results of a randomised phase III trial by the EORTC brain and RT groups and NCIC clinical trials group [abstract no. 2]. Proc Am Soc Clin Oncol 2004; 22(145): 15

31.

Paul MJ, Summers Y, Calvert H, et al. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res 2002; 12(2): 175–8PubMedCrossRef

32.

Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004; 22: 2101–7PubMedCrossRef

33.

Kleeburg UR, Engel E, Israels P, et al. Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and effectiveness: a multi-centre phase II trial of the EORTC-melanoma cooperative group (MCG). Melanoma Res 1995; 5: 195–200

34.

Avril MF, Aamdal S, Grob JJJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004; 22: 1118–25PubMedCrossRef

35.

Middleton MR, Lee SM, Arance A, et al. O⁶-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study. Int J Cancer 2000; 88(3): 469–73PubMedCrossRef

36.

Dolan ME, Posner M, Karrison T, et al. Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically respectable tumours. Clin Cancer Res 2002; 8: 2519–23PubMed

37.

Tentori L, Leonetti C, Scarsella M, et al. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumour activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 2003; 9: 5370–9PubMed

38.

Hu Y, Cherton-Horvat G, Dragowska V, et al. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res 2003; 9(7): 2826–36PubMed

39.

Amiri KI, Horton LW, LaFleur BJ, et al. Augmenting chemosensitivity of malignant melanoma tumours via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res 2004; 64: 4912–8PubMedCrossRef

40.

Eisen T, Boshoff C, Mak I, et al. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000; 14 (13 Suppl.): 17–20

41.

Danson S, Lorigan P, Arance A, et al. A randomised study of temozolomide (TMZ) alone, with interferon (TMZ-IFN) or with thalidomide (TMZ-THAL) in metastatic malignant melanoma (MMM). J Clin Oncol 2003; 21(13): 2551–7PubMedCrossRef

42.

Hwu WJ, Krown SE, Menell JH, et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 2003; 21(17): 3351–6PubMedCrossRef

43.

Dredge K, Marriott JB, Macdonald CD, et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002; 87(10): 1166–72PubMedCrossRef

44.

Bartlett JB, Michael A, Clarke IA, et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of the thalidomide analogue CC-5013 in patients with metastatic melanoma and other advanced cancers. Br J Cancer 2004; 90(5): 955–61PubMedCrossRef

45.

Tucker GC. Alpha v integrin inhibitors and cancer therapy [erratum appears in Curr Opin Investig Drugs 2003; 4: 1140]. Curr Opin Investig Drugs. 2003 Jun; 4(6): 722–31PubMed

46.

Peterson AC, Swiger S, Stadler W, et al. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in patients with advanced melanoma [abstract no. 2863]. Proc Am Soc Clin Oncol 2003; 22: 712

47.

Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal carcinoma. N Engl J Med 2004; 350(23): 2335–42PubMedCrossRef

48.

Carsons WE, Biber J, Shah N, et al. A phase 2 trial of a recombinant humanised monoclonal anti-vascular endothelial growth factor (VEGF) antibody in patients with malignant melanoma [abstract no. 2873]. Proc Am Soc Clin Oncol 2003; 22: 715

49.

Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949–54PubMedCrossRef

50.

Casula M, Colombino M, Satta MP, et al. BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian Melanoma Intergroup Study. J Clin Oncol 2004; 22(2): 286–92PubMedCrossRef

51.

Rivers JK. Is there more than one road to melanoma? Lancet 2004; 363: 728–30PubMedCrossRef

52.

Hingorani SR, Jacobetz MA, Robertson GP, et al. Suppression of BRAF^V599E in human melanoma abrogates transformation. Cancer Res 2003; 63: 5198–202PubMed

53.

Collisson EA, De A, Suzuki H, et al. Treatment of metastatic melanoma with an orally available inhibitor of the ras-raf-MAPK cascade. Cancer Res 2003; 63: 5669–73PubMed

54.

Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumour activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis. Cancer Res 2004; 64: 7099–109PubMedCrossRef

55.

Ahmad T, Marais R, Pyle L, et al. BAY 43-9006 in patients with advanced melanoma: the Royal Marsden experience [abstract no. 7506]. Proc Am Soc Clin Oncol 2004; 22(145): 7115

56.

Flaherty KT, Brose M, Schuchter L, et al. Phase I/II trial of BAY 43-9006, carboplatin and paclitaxel demonstrates preliminary antitumour activity in the expansion cohort patients with metastatic melanoma [abstract no. 7507]. Proc Am Soc Clin Oncol 2004; 22(145): 7115

57.

Sparrow LE, Heenan PJ. Differential expression of epidermal growth factor receptor melanocytic tumours demonstrated by immunohistochemistry and mRNA in situ hybridization. Australas J Dermatol 1999; 40(1): 19–24PubMedCrossRef

58.

Inman JL, Kute T, White W. Absence of HER2 overexpression in metastatic malignant melanoma. J Surg Oncol 2003; 84(2): 82–8PubMedCrossRef

59.

Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia. N Engl J Med 2001; 344: 1031–7PubMedCrossRef

60.

Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumours. N Engl J Med 2002; 347: 472–80PubMedCrossRef

61.

Janku F, Tomancova V, Novotny J, et al. Expression of c-kit was found in more than 50% of early stages melanoma: a retrospective study of 261 patients [abstract no. 2864]. Proc Am Soc Clin Oncol 2003; 22: 712

62.

Wyman K, Atkins MB, Hubbard F, et al. A phase II trial of imatinib mesylate at 800mg daily in metastatic melanoma: lack of clinical efficacy with significant toxicity [abstract no. 2865]. Proc Am Soc Clin Oncol 2003; 22: 713

63.

National Cancer Institute (NCI). Clinical trials [online]. Available from URL: http://www.cancer.gov/search/clinicaltrials [Accessed 2005 Feb 2]

64.

Hansson M, Hermodsson S, Brune M, et al. Histamine protects T cells and natural killer cells against oxidative stress. J Interferon Cytokine Res 1999; 19: 1135–44PubMedCrossRef

65.

Asea A, Hermodsson S, Hellstrand K. Histaminergic regulation of natural killer cell-mediated clearance of tumour cells in mice. Scand J Immunol 1996; 43: 9–15PubMedCrossRef

66.

Hellstrand K, Naredi P, Lindner P, et al. Histamine in immunotherapy of advanced melanoma: a pilot study. Cancer Immunol Immunother 1994; 39: 416–9PubMedCrossRef

67.

Maxim Pharmaceuticals Press Conference. Maxim Pharmaceutical phase 3 trial for advanced melanoma fails to meet primary endpoint [media release]. 2004 Sep 20

68.

Hauschild A. First analysis of international M-02 trial: histamine, interferon alpha-2b (IFN), interleukin (IL)-2 vs dacarbazine (DTIC) [oral presentation]. European conference: Perspectives in Melanoma Management; 2003 Oct 10–11; Amsterdam

69.

Sosman JA, Weeraranta AT, Sondak VK. When will melanoma vaccines be proven effective? J Clin Oncol 2004; 22(3): 387–9PubMedCrossRef

70.

Livingstone PO, Wong GY, Adluri S, et al. Improved survival in stage III melanoma patients with GM2 antibodies, a randomised trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994; 5: 1036–44

71.

Kirkwood JM, Ibrahim JG, Sosman JA, et al. High dose interferon alpha 2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001; 19(9): 2370–80PubMed

72.

Marchard M, von Baren N, Weynants P, et al. Tumour regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-Al. Int J Cancer 1999; 80: 219–30CrossRef

73.

Cebon J, Jager E, Shackleton MJ, et al. Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenze peptides in subjects with advanced malignant melanoma. Cancer Immun 2003; 16: 3–7

74.

Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 321–7PubMedCrossRef

75.

Kirkwood J, Lee S, Land S, et al. E1696: final analysis of the clinical and immunological results of a multi-centre ECOG phase II trial of multi-epitope peptide vaccination for stage IV disease with MART-1, gp1000 and tyrosinase [abstract no. 7502]. Proc Am Soc Clin Oncol 2004; 22(145): 7105

76.

David I, Chen W, Jackson H, et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A 2004; 101: 10697–702CrossRef

77.

Sosman JA, Unger JM, Liu PY, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumour vaccine: impact of HLA class I antigen expression on outcome. Southwest Oncology Group. J Clin Oncol 2002; 20(8): 2067–75

78.

Morton DL, Eilber FR, Holmes EC, et al. Preliminary results of a randomised trial of adjuvant immunotherapy in patients treated with malignant melanoma who have lymph node metastases. Aust N Z J Surg 1978; 48: 49–52PubMedCrossRef

79.

Chan AD, Morton DL. Active immunotherapy with allogeneic tumour cell vaccines: present status. Semin Oncol 1998; 25: 611–22PubMed

80.

Belli F, Testori A, Rivoltini L, et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 2002; 20(20): 4169–80PubMedCrossRef

81.

Soiffer R, Hodi FS, Haluska F, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003; 21(17): 3343–50PubMedCrossRef

82.

Smith CL, Dunbar PR, Palmowski MJ, et al. Results of a phase I study evaluating ‘prime-boost’ therapeutic vaccination strategies using a string of melanoma-derived CD8+ T cell epitopes in stage II/III/IV melanoma patients [abstract no. 702]. Proc Am Soc Clin Oncol 2003; 22: 175CrossRef

83.

Smith C, Dunbar P, Mirza F, et al. Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int J Cancer 2005; 113(2): 259–66PubMedCrossRef

84.

Kugler A, Stuhler G, Waiden P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumour cell-dendritic cell hybrids. Nat Med 2000; 6: 332–6PubMedCrossRef

85.

Bedrosian I, Mick R, Xu S, et al. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol 2003; 21(20): 3826–35PubMedCrossRef

86.

Schadendorf D, Nestle FO, Broecker E-B, et al. Dacarbazine versus vaccination with autologous peptide-pulsed dendritic cells as first-line treatment of patients with metastatic melanoma: results of a prospective-randomised phase III study [abstract no. 7508]. Proc Am Soc Oncol 2004; 22(145): 7125

87.

Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumour lymphocytes. Science 2002; 298: 850–4PubMedCrossRef

88.

Phan GQ, Yang J, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen4 blockade in patients with metastatic melanoma. Proc Nat Acad Sci U S A 2003; 100: 8372–7CrossRef

89.

Hersh E, Weber J, Powderly J, et al. A phase II randomised multi-centre study of MDX-010 alone or in combination with DTIC in stage IV malignant melanoma [abstract no. 7511]. Proc Am Soc Clin Oncol 2004; 22(145): 7125

90.

Schneeder A, Wagner C, Zemann A, et al. CpG motifs are efficient adjuvants for DNA vaccines. J Invest Dermatol 2004; 123: 371–9CrossRef

Titel: Improving Outcomes in Advanced Malignant Melanoma
Update on Systemic Therapy
verfasst von: Dr Sarah Danson
Paul Lorigan
Publikationsdatum: 01.04.2005
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 6/2005
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200565060-00002

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Improving Outcomes in Advanced Malignant Melanoma

Update on Systemic Therapy

Abstract

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2005

Tacrolimus Ointment

Valganciclovir

Peginterferon-α-2a (40kD)

Mycophenolate Sodium Delayed Release

Mycophenolate Sodium Delayed Release

Bronchiolitis Obliterans Syndrome